A “typically bad” week for the general market (NASDAQ composite off -1.6%). And also “typically”, the two Biotech indices having divergent performance, in that the NASDAQ Biotech index was essentially flat for the week, while the S&P Biotech shed -4.4%
Looking at the individual issues, we saw moves for the week from +39% to+130% for the top five, but with one exception these all seemed to just be responding to positive earnings reports issued at the end of last week. The exception, PDSB (up 54.4% for the week), not only had “exceeds expectations” earnings, but also reported “100% positive response” in the Phase II study of a immunotherapy based treatment of cervical cancer. Even these big moves were not all that significant in terms of the contest, in that they were starting from large negative YTD performances. Even PDSB only managed to eke its way into the black (YTD +2.6%). The exception is GLYC in that its 81% improvement for the week, put it at a YTD of +56%.
Mind you, good “earnings” in biotech often means lower than anticipated losses.
The median contest portfolio lost -1.1% for the week, but the average was UP +0.2%, undoubtedly a reflection of the fact that PDSB appears in five contest portfolios, which returned the second through sixth best performance for the week. The number one spot is GENEGURU’s +18% return for the week, thanks to their position in GLYC. This propelled them into second place in the YTD rankings, zooming past last weeks best performer, MOPGCW. Of even greater significance, GENEGURU is now only 4.7% behind number one DIEGOSAN, who not only stayed in first place with this week's return of +0.9%, but once again managed to edge their portfolio over the line into the black, +0.85% YTD. (There were no new/returning members in the Top 10 YTD club this week.)
That a single stock can show such impressive weekly gains means that the contest is by no means decided. Another result like MACK, that benefited MOPGCW last week, would put any portfolio in the top thirteen into the lead.
Everyone should be polishing their crystal balls, or dusting off their dart boards, as it will soon be time for next year’s picks. Next week, we’ll go over the rules.
|
Report Time Ranges
|
|
|
From
|
To
|
Recent
|
11/11/2022
|
11/18/2022
|
YTD
|
12/31/2021
|
Index Performance
|
|
Symbol
|
Recent
|
YTD
|
|
^IXIC
|
-1.57%
|
-28.76%
|
^NBI
|
-0.02%
|
-10.16%
|
^SPSIBI
|
-4.44%
|
-27.55%
|
Share Performance
|
Recent
|
YTD
|
Selected Top 6
|
Bottom 5
|
Top 5
|
Bottom 5
|
AMBS
|
131.250%
|
STSA
|
-83.951%
|
MACK
|
217.65%
|
GNCA
|
-99.14%
|
GLYC
|
81.452%
|
STOK
|
-35.869%
|
CBIO
|
131.30%
|
ATHX
|
-97.40%
|
CABA
|
63.445%
|
DNA
|
-23.158%
|
BIOA-B.ST
|
109.64%
|
PLXP
|
-95.84%
|
PDSB
|
54.464%
|
CYCC
|
-22.873%
|
FENC
|
95.00%
|
OTIC
|
-95.48%
|
PRQR
|
38.629%
|
NVTA
|
-21.330%
|
PCVX
|
85.12%
|
PTE
|
-95.44%
|
|
Top 10 Portfolios YTD
|
YTD(Portfolio - SPSIBI)
|
Rec
|
Rec(Port. - SPSIBI)
|
DIEGOSAN
|
0.85%
|
28.40%
|
0.940%
|
5.377%
|
GENEGURU
|
-3.79%
|
23.76%
|
17.558%
|
21.995%
|
MOPGCW
|
-13.50%
|
14.05%
|
-0.772%
|
3.665%
|
TECHNETIUM
|
-16.90%
|
10.65%
|
-0.747%
|
3.689%
|
DEW DILIGENCE
|
-21.12%
|
6.43%
|
0.951%
|
5.387%
|
BRENDAN_49
|
-25.54%
|
2.01%
|
-7.131%
|
-2.695%
|
BIOSCIENTISTSA
|
-25.70%
|
1.85%
|
-0.311%
|
4.126%
|
A.J. MULLEN
|
-26.52%
|
1.03%
|
-2.279%
|
2.158%
|
ROCKY9
|
-27.63%
|
-0.08%
|
-4.103%
|
0.334%
|
HORSEINALFALFA
|
-28.30%
|
-0.75%
|
-1.806%
|
2.631%
|
Average and Median Portfolio Performance
|
|
Avg Recent
|
Avg YTD
|
Median Recent
|
Median YTD
|
|
$24
|
-36.36%
|
ECCU
|
-$730
|
BIO-TITAN
|
-37.56%
|
0.18%
|
RAJU_BIJLEE
|
-1.142%
|
|
